Tralokinumab for adults with AD – first-time results of long-term use

More long-term treatments are needed for patients suffering from moderate-to-severe atopic dermatitis (AD). In this MEDtalk, Dermatologist Andrew Blauvelt presents promising long-term data on the safety and efficacy of tralokinumab plus optional topical corticosteroids in this group of patients.